Yposkesi: SK Inc.'s French bio arm sets to facility expansion

SK Inc.'s French bio subsidiary Yposkesi is set to build a second commercial bioproduction site in an effort to expand its footprint in the global biopharmaceutical market, officials said Monday. The French company has announced the launch of project SKY, a plan to inject some 58 million euros ($70 million) in the construction of its new manufacturing plant. Slated for completion by 2023, the forthcoming facility will be one of the largest advanced therapy medicinal product, or ATMP,